VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q1 2023
Holdings as of Mar 31, 2023, filed May 15, 2023. Long positions only; changes compare share counts with Q4 2022.
- Positions
- 25
- −3 vs. Q4 2022
- Portfolio value
- $512.2M
- −$81.4M (−13.7%) vs. Q4 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| VRDNViridian Therapeutics, Inc. | COM | 2,699,865 | $68.7M | 13.4% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 4,884,977 | $52.7M | 10.3% | +846,860+21.0% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 2,214,142 | $48.5M | 9.5% | +2,214,142 | New | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 3,619,522 | $42.9M | 8.4% | −88,369−2.4% | Reduced | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,430,000 | $38.0M | 7.4% | +350,000+32.4% | Added | History |
| AMAMAmbrx Biopharma Cayman, Inc. | SPONSORED ADS | 3,298,577 | $29.4M | 5.7% | +3,298,577 | New | History |
| GHRSGH Research PLC | ORDINARY SHARES | 3,517,125 | $28.1M | 5.5% | 00.0% | Unchanged | History |
| DICEDICE Therapeutics, Inc. | COM | 819,000 | $23.5M | 4.6% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 2,916,667 | $22.9M | 4.5% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 1,226,214 | $22.6M | 4.4% | 00.0% | Unchanged | History |
| CELCCelcuity Inc. | COM | 2,105,386 | $21.6M | 4.2% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 833,927 | $16.8M | 3.3% | +86,058+11.5% | Added | History |
| CABACabaletta Bio, Inc. | COM | 1,973,251 | $16.3M | 3.2% | +77,966+4.1% | Added | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 1,866,000 | $15.9M | 3.1% | 00.0% | Unchanged | – |
| ANNXAnnexon, Inc. | COM | 3,220,050 | $12.4M | 2.4% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 6,351,531 | $12.4M | 2.4% | 00.0% | Unchanged | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 2,208,812 | $8.70M | 1.7% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,040,754 | $8.42M | 1.6% | −3,523,208−77.2% | Reduced | History |
| THRXTheseus Pharmaceuticals, Inc. | COM | 770,000 | $6.84M | 1.3% | +770,000 | New | History |
| TRVITrevi Therapeutics, Inc. | COM | 3,050,022 | $5.64M | 1.1% | 00.0% | Unchanged | History |
| FULCFulcrum Therapeutics, Inc. | COM | 1,307,094 | $3.73M | 0.7% | +859,768+192.2% | Added | History |
| LYRALyra Therapeutics, Inc. | COM | 924,170 | $1.86M | 0.4% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 1,000,000 | $1.75M | 0.3% | +1,000,000 | New | History |
| RLYBRallybio Corp | COM | 268,532 | $1.53M | 0.3% | 00.0% | Unchanged | History |
| Affimed N VN01045108 | COM | 1,428,571 | $1.07M | 0.2% | 00.0% | Unchanged | – |
Sold out since Q4 2022 (7)
Positions held at the end of Q4 2022 that are gone from this filing.
| Security | Class | Shares in Q4 2022 | Value in Q4 2022 | % of portfolio in Q4 2022 | History |
|---|---|---|---|---|---|
| AXSMAxsome Therapeutics, Inc. | COM | 670,718 | $51.7M | 8.7% | History |
| NVAXNovavax Inc | COM NEW | 1,879,894 | $19.3M | 3.3% | History |
| PRVBProvention Bio, Inc. | COM | 1,118,653 | $11.8M | 2.0% | History |
| LIANYLianBio | SPONSORED ADS | 4,793,047 | $7.86M | 1.3% | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 1,770,705 | $7.05M | 1.2% | History |
| INZYInozyme Pharma, Inc. | COM | 2,709,987 | $2.85M | 0.5% | History |
| ATYRaTYR PHARMA INC | COM NEW | 1,171,436 | $2.57M | 0.4% | History |